10x Genomics reported revenue of USD 166.03 million for the fourth quarter (Q4) of 2025, representing a 1% increase. Gross margin for the quarter was 68%, compared to 67% for the same period in the prior year. For the full year (FY) 2025, total revenue was USD 642.82 million. Products and services revenue reached USD 596.69 million in FY 2025, while license and royalty revenue totaled USD 46.14 million. The company ended the year with USD 523.4 million in cash, cash equivalents, and marketable securities, reflecting an increase of USD 130 million over the prior year. During the period, 10x Genomics CEO Serge Saxonov noted disciplined execution amid a challenging environment and highlighted strengthening business fundamentals. The company reported expanding impact from its platforms, driven by product innovations and strategic partnerships. 10x Genomics also cited positioning for growth in areas including AI-driven demand, translational research, and emerging clinical opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.